ERR open access journal advertisement
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

EUROPEAN RESPIRATORY REVIEW, 2007;16: 88. doi:10.1183/09059180.00010406
© 2007 the European Respiratory Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Post-meeting note

Following the symposium "Anti-IgE: changing lives in clinical practice?", the Global Initiative for Asthma (GINA) guidelines were revised in November 2006 [1]. The GINA classification of asthma by severity based on clinical features is still considered useful when decisions are being made about management at the initial assessment of a patient. However, the GINA 2006 guidelines no longer recommend that treatment decisions are based on asthma severity classification, but that they should instead be based on the level of asthma control and current treatment.

According to the GINA 2006 guidelines, treatment should be tailored to each patient's asthma control and current treatment (step 1–5), with treatment progressing to the next step if control is not achieved [1]. Rapid-acting ß2-agonists are recommended at step 1; low-dose inhaled corticosteroids and, if needed, long-acting ß2-agonists are recommended at steps 2 and 3. Daily treatment with medium- or high-dose inhaled corticosteroids in combination with a long-acting ß2-agonist is recommended at treatment step 4, with additional controller medication if needed (sustained-release theophyllines and/or leukotriene modifiers). Anti-immunoglobulin E (omalizumab) and oral corticosteroids are included at step 5 (fig. 1Go).


Figure 1
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 1. Global Initiative for Asthma 2006 guidelines for asthma treatment in patients aged ≥5 yrs. ICS: inhaled corticosteroids; LABA: long-acting ß2-agonist. Ig: immunoglobulin. #: receptor antagonist or synthesis inhibitor. Reproduced, with modifications, from [1] with permission from the publisher.

 

REFERENCES

  1. Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publication No 02-3659 (revised 2006). National Institutes of Health/National Heart, Lung, and Blood Institute, 2006




This Article
Right arrow Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS